Shares of Hansen Medical (NSDQ:HNSN) slid last week after an analyst at Morgan Stanley said he would stop covering the robot-assisted surgery device maker, citing competitive issues and a capitalization problem. “We expect Hansen to underperform our coverage and the broader market largely due to our view that Hansen’s penetration into endovascular procedures will have a much slower […]
Stryker evaluates acquisition of orthopedics rival Smith & Nephew | Medtech Wall Street news for the week of June 2, 2014
What if Stryker bought Smith & Nephew?
May 29, 2014 by Brad Perriello
Stryker CEO Kevin Lobo yesterday admitted that his company was evaluating an acquisition of British orthopedics rival Smith & Nephew.
What if Stryker bought Smith & Nephew?
CFN taps BSX exec for board | Medtech personnel moves for the week of May 12, 2014
Medtech makers continue shift in CEO pay
Image © 2014 Morgan Stanley. Click image to enlarge.
Teleflex announces plans to cut costs and streamline manufacturing | Medtech Wall Street news for the week of May 5, 2014
Morgan Stanley: Medtech underperformed in April
The medical device sector under-performed the S&P 500 index in April after a sharp swing over-performance during the 1st quarter, according to analysts at Morgan Stanley.
The 30 medtech stocks Morgan Stanley covers collectively under-performed the S&P by 4.1%, after besting the index by 4.9% during the 1st quarter.
Medtronic CFO: Size matters
Abbott details $15B AbbVie spinout financing | Wall Street Beat
MassDevice.com +7 | The top 7 med-tech stories for the week of June 1, 2012.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Morgan Stanley: “Device tax likely won’t be repealed on this attempt”
Morgan Stanley analysts are slightly more confident this month that the medical device tax might be repealed, but they don’t see it happening this year.
The odds of repeal are up to 30% from just 10% last month, according to a report published by the financial services firm, but the measure isn’t likely to make it through the Democrat-led Senate. But the fight won’t end there.
